Fosun Pharma USA Inc
General
Total Cases2
Active Cases1
Patents--
Ratings
Experience
Grade
Trend
DCT
L3
E
PTAB
L1
D
CAFC
--
--
--
Analytics
Cases
Litigated Patents
Ratings Trends
Recent Dockets
Entered | Case | Description |
|---|---|---|
| 12/23/24 | MOTION in Limine to Exclude Expert Testimony of Dr. Suter Pursuant to Fed. R. Evid. 702 by LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA PHARMA, LLC, THE GEORGE WASHINGTON UNIVERSITY. (Attachments: # [1] Brief, # [2] Text of Proposed Order)(CHEVALIER, CHARLES) (Entered: 12/23/2024) | |
| 12/23/24 | BRIEF in Support filed by LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA PHARMA, LLC, THE GEORGE WASHINGTON UNIVERSITY re [274] MOTION in Limine to Preclude Testimony, Evidence or Argument Regarding Non-Public FDA Correspondence Regarding Giapreza Label (CHEVALIER, CHARLES)NOTICE TO COUNSEL: Counsel is advised that pursuant to Local Civil Rule 5.3(c)(2), a single, consolidated motion to seal shall be filed within 14 days following the completed briefing of the materials sought to be sealed, or within 14 days following the date on which the last of such materials was filed under temporary seal if the motion is resolved, unless otherwise directed by the Court. (Entered: 12/23/2024) | |
| 12/23/24 | MOTION in Limine to Preclude Testimony, Evidence or Argument Regarding Non-Public FDA Correspondence Regarding Giapreza Label by LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA PHARMA, LLC, THE GEORGE WASHINGTON UNIVERSITY. (Attachments: # [1] Text of Proposed Order)(CHEVALIER, CHARLES) (Entered: 12/23/2024) | |
| 12/23/24 | MOTION in Limine to Exclude Undisclosed Invalidity References and Objection to Magistrate Judge Clark's Ruling by LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA PHARMA, LLC, THE GEORGE WASHINGTON UNIVERSITY. (Attachments: # [1] Brief, # [2] Declaration of Charles H. Chevalier, Esq., # [3] Exhibit A, # [4] Text of Proposed Order)(CHEVALIER, CHARLES) (Entered: 12/23/2024) | |
| 12/23/24 | MOTION in Limine regarding Expert Testimony and Septic Shock by FRESENIUS KABI USA LLC, FRESENIUS KABI SWISSBIOSIM GMBH, GLAND PHARMA LIMITED. (Attachments: # [1] Brief, # [2] Declaration of James Richter, # [3] Text of Proposed Order)(RICHTER, JAMES) (Entered: 12/23/2024) | |
| 12/23/24 | MOTION in Limine regarding Expert Testimony and Secondary Considerations by FRESENIUS KABI USA LLC, FRESENIUS KABI SWISSBIOSIM GMBH, GLAND PHARMA LIMITED. (Attachments: # [1] Brief, # [2] Declaration of James Richter, # [3] Text of Proposed Order)(RICHTER, JAMES) (Entered: 12/23/2024) | |
| 12/23/24 | MOTION in Limine regarding Expert Testimony on Refractory Hypotension by FRESENIUS KABI USA LLC, FRESENIUS KABI SWISSBIOSIM GMBH, GLAND PHARMA LIMITED. (Attachments: # [1] Brief, # [2] Declaration of James Richter, # [3] Text of Proposed Order)(RICHTER, JAMES) (Entered: 12/23/2024) | |
| 12/23/24 | MOTION in Limine regarding Dr. Chawla by FRESENIUS KABI USA LLC, FRESENIUS KABI SWISSBIOSIM GMBH, GLAND PHARMA LIMITED. (Attachments: # [1] Brief, # [2] Declaration of James Richter, # [3] Text of Proposed Order)(RICHTER, JAMES) (Entered: 12/23/2024) | |
| 12/20/24 | STATEMENT Pursuant to 35 USC 282 by FRESENIUS KABI USA LLC, FRESENIUS KABI SWISSBIOSIM GMBH, GLAND PHARMA LIMITED. (RICHTER, JAMES) (Entered: 12/20/2024) | |
| 12/20/24 | TEXT ORDER: As proposed in the Plaintiffs' letter, ECF 266, the Court will treat the referenced forthcoming motion in limine as an objection pursuant to Federal Rule of Civil Procedure 72(a). So Ordered by Judge Michael E. Farbiarz on 12/20/2024. (ro, ) (Entered: 12/20/2024) |